This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merrimack Pharmaceuticals Inc (MACK)

NASDAQ: Health Care

Company Cash Flow
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Cash Flow From Operating Activities
Net Income (Loss) -83.56M -130.68M -91.75M -79.68M
Operating Gains/Losses 0.00 0.00 0.00 864.00K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables 2.59M 3.41M -1.84M -3.68M
(Increase) Decrease in Inventories 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Current Assets 0.00 -1.81M -2.35M 0.00
(Decrease) Increase In Payables -646.00K 13.30M 6.98M 3.22M
(Decrease) Increase In Other Current Liabilities 0.00 0.00 0.00 5.60M
(Increase) Decrease In Other Working Capital 20.19M -1.88M 1.58M 13.25M
Other Non-Cash Items 22.57M 15.86M 6.38M 6.95M
Net Cash From Continuing Operations -34.81M -95.18M -79.82M -52.82M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -34.81M -95.18M -79.82M -52.82M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 111.86M 0.00 0.00 0.00
Purchases of Property, Plant & Equipment -6.04M -9.86M -3.19M -3.75M
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments 0.00 0.00 0.00 0.00
Other Cash from Investing Activities -2.00K -59.00K -247.00K 7.00K
Cash Provided by Financing Activities
Net Cash From Investing Activities -6.01M -27.74M -75.22M -3.75M
Issuance of Debt 1.04M 121.54M 41.13M 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 10.38M 28.75M 105.45M 78.69M
Repayment of Long-Term Debt 0.00 0.00 -48.00K -443.00K
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends -7.00K -3.00K -4.24M 0.00
Other Financing Charges, Net 0.00 0.00 0.00 -1.95M
Net Cash From Financing Activities 11.42M 150.29M 142.30M 76.30M
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents -29.40M 27.37M -12.74M 19.74M
MACK News

MACK Merrimack Pharmaceuticals Inc

Chart of MACK

Analysts Ratings for MACK

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 6 6 6 5
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET MACK ANALYST REPORT

Brokerage Partners

MACK Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs